Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures

Neurology

Volumn 75, Issue 21, 2010, Pages 1920-1927

  Politis, M ^a   Wu, K ^a   Loane, C ^a   Turkheimer, F E ^a   Molloy, S ^b   Brooks, D J ^a   Piccini, P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 4 (2 DIMETHYLAMINOMETHYLPHENYLTHIO)BENZONITRILE C 11; APOMORPHINE; BENSERAZIDE; BROMOCRIPTINE; CABERGOLINE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; RADIOLIGAND; ROTIGOTINE; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

AGED; AMYGDALOID NUCLEUS; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; DEPRESSION INVENTORY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE MARKER; DRUG BINDING; FEMALE; HAMILTON SCALE; HUMAN; HYPOTHALAMUS; LIMBIC SYSTEM; MALE; MOOD DISORDER; NEUROTRANSMISSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PATIENT CODING; PRIORITY JOURNAL; RAPHE NUCLEUS; RATING SCALE; SCORING SYSTEM; SEROTONIN BLOOD LEVEL; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; STRUCTURED INTERVIEW;

BENZYLAMINES; CARBON RADIOISOTOPES; DEPRESSION; HUMANS; LIMBIC SYSTEM; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; RAPHE NUCLEI; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TISSUE DISTRIBUTION; UP-REGULATION;

EID: 78650030521     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181feb2ab     Document Type: Article

References (40)

1. Taylor A, Saint-Cyr JA, Lang AE, Kenny FT. Parkinson's disease and depression: A critical re-evaluation. Brain 1986; 109:279-292.
2. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J Nerv Ment Dis 1990; 178:27-31.
3. Dooneef G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992;49:305-307.
4. Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry 1999;14: 711-718.
5. Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson's disease. Mov Disord 2000;15:216-223.
6. McDonald WM. Depression. In: Parkinson's Disease: Diagnosis and Clinical Management: 2nd ed. New York: Demos Medical Publishing; 2008:159-173.
7. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.
8. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: A review and metaanalysis. Mov Disord 2005;20:1161-1169.
9. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128:1314-1322.
10. Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: On movement, mood, and madness. Mov Disord 2009;24:1255-1266.
11. Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1062-1073.
12. Boileau I, Warsh JJ, Guttman M, et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB. Mov Disord 2008;23:1776-1780.
13. Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S. Positron emission tomography quantification of [(11)C]- DASB binding to the human serotonin transporter: Modeling strategies. J Cereb Blood Flow Metab 2001;21: 1342-1353.
14. Ichise M, Liow JS, Lu JQ, et al. Linearized reference tissue parametric imaging methods: Application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 2003;23:1096-1112.
15. Parkin SG, Gregory RP, Scott R, et al. Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: A case series of 115 patients. Mov Disord 2002;17:682-692.
16. Leentjens AF, Verhey FR, Luijckx GJ, Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord 2000;15:1221-1224.
17. Silberman CD, Laks J, Capitaö CF, Rodrigues CS, Moreira I, Engelhardt E. Recognizing depression in patients with Parkinson's disease: Accuracy and specificity of two depression rating scale. Arq Neuropsiquiatr 2006;64: 407-411.
18. Dissanayaka NN, Sellbach A, Matheson S, et al. Validity of Hamilton Depression Inventory in Parkinson's disease. Mov Disord 2007;22:399-403.
19. Brix G, Zaers J, Adam LE, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol: National Electrical Manufacturers Association. J Nucl Med 1997;38:1614-1623.
20. Praschak-Rieder N, Willeit M, Wilson AA, Houle S, Meyer JH. Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry 2008;65:1072-1078.
21. Kish SJ, Furukawa Y, Chang LJ, et al. Regional distribution of serotonin transporter protein in postmortem human brain: Is the cerebellum a SERT-free brain region? Nucl Med Biol 2005;32:123-128.
22. Duvernoy HM. The Human Brain: Surface, Blood Supply, and Three-dimensional Sectional Anatomy, 2nd ed. New York: Springer-Verlag; 1999.
23. Montgomery AJ, Thielemans K, Mehta MA, Turkheimer F, Mustafovic S, Grasby PM. Correction of head movement on PET studies: Comparison of methods. J Nucl Med 2006;47:1936-1944.
24. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
25. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27:1533-1539.
26. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: A quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986;49:381-389.
27. Judd LL, Rapaport MH, Paulus MP, Brown JL. Subsyndromal symptomatic depression: A new mood disorder? J Clin Psychol 1994;55(suppl):18-28.
28. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004; 52:784-788.
29. Barbas NR. Cognitive, affective, and psychiatric features of Parkinson's disease. Clin Geriatr Med 2006;22:773-796.
30. Mayeux R, Stern Y, Williams JB, Cote L, Frantz A, Dyrenfurth I. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986;143:756-759.
31. Robins AH. Depression in patients with parkinsonism. Br J Psychiatry 1976;128:141-145.
32. Veiga BA, Borges V, Silva SM, Goulart Fde O, Cendoroglo MS, Ferraz HB. Depression in Parkinson's disease: Clinical-epidemiological correlates and comparison with a controlled group of non-parkinsonian geriatric patients. Rev Bras Psiquiatr 2009;31:39-42.
33. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997;12: 756-759.
34. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson's disease: A prospective study. Mov Disord 2000;15:986-989.
35. Menza M, Marin H, Kaufman K, Mark M, Lauritano M. Citalopram treatment of depression in Parkinson's disease: The impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 2004;16:315-319.
36. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebocontrolled study. Mov Disord 2008;23:850-857.
37. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-892.
38. Okun MS, Fernandez HH. Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients? Neurology 2009;72:868-869.
39. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: A randomised, double-blind, placebocontrolled trial. Lancet Neurol 2010;9:573-580.
40. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: Critique and recommendations. Mov Disord 2007;22:1077-1092.